樂普生物-B(02157.HK)成功配售5117萬股 淨籌2.3億港元
格隆匯5月24日丨樂普生物-B(02157.HK)宣佈,配售協議所載的配售事項的所有條件(包括(其中包括)上市委員會批准配售股份上市及買賣)均已獲達成,且配售事項已於2024年5月24日完成。
公司已成功按配售價每股配售股份4.58港元向不少於六名承配人配售合共5117萬股配售股份,分別佔經配發及發行配售股份擴大後的全部已發行H股及全部已發行股份約3.09%及2.99%。
配售事項所得款項總額及所得款項總淨額將分別為約2.34以港元及約2.30億港元。配售事項所得款項淨額(i)約70%(即1.61億港元)將用於公司ADC候選產品的研發、臨牀試驗、註冊備案及其他工作流程;(ii)約20%(即4595萬港元)將用於公司溶瘤病毒候選產品CG0070的臨牀試驗及其他工作流程;及(iii)約10%(即2298萬港元)將用於補充公司流動資金及作一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.